NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Diagnostics & Research · USD

iSpecimen Inc. (ISPC) Stock Analysis

iSpecimen Inc. (ISPC) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ISPC

$0.89

−$0.07 (−7.02%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ISPC with… →

ISPC Key Statistics

As of Oct 21, 2026
Trading
Open
$0.93
Previous Close
$0.96
Day's Range
0.88–0.95
52-Week Range
0.88–36.32
Volume
70.39K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.65
Valuation
Market Cap
$2.25M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.82
EPS (ttm)Profit attributable to each share over the last twelve months.
−52.98
Financials (FY)
Revenue (FY)
$1.93M−79.24%
Net Income (FY)
−$10.49M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
2.52M
1-Year Return
−97.29%
Dividend and dates
Avg Volume
669.44K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ISPC closed at $0.89, −97.29% over 1 year.

iSpecimen Inc. (ISPC) has a market capitalization of $2.25M.

In fiscal 2025, ISPC reported revenue of $1.93M.

ISPC Stock Return by Calendar Year

iSpecimen Inc. (ISPC) return since Jun 2021: what $10,000 became

1 year
$10,000 $271
−97.29%
5 years
$10,000 $1
−99.99%
Since Jun 2021
$10,000 $2
−99.98%

If you had invested $10,000 in iSpecimen Inc. (ISPC) at the close on June 17, 2021, the earliest close on record here, it would have been worth $2 at the close on October 21, 2026: −99.98% in total, −80.60% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−91.42%
2025−90.21%
2024−73.50%
2023−63.56%
2022−82.39%
2021 (partial year)+9.23%

As of October 21, 2026.

ISPC Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.93M−$10.49M−543.7%
2024$9.29M−$12.50M−134.5%
2023$9.93M−$11.10M−111.8%
2022$10.40M−$10.25M−98.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.93M$24.11K−$8.98M−$10.49M−543.7%
2024$9.29M$3.99M−$12.73M−$12.50M−134.5%
2023$9.93M$5.11M−$11.17M−$11.10M−111.8%
2022$10.40M$5.65M−$10.19M−$10.25M−98.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ISPC Valuation vs Diagnostics & Research Median

Median of 45 stocks
MetricISPCDiagnostics & Research medianvs median
P/S ratio4.825.238% below

Medians across 45 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

iSpecimen Inc. (ISPC) carries a market capitalisation of $2.25M. It is classified in the Diagnostics & Research industry, within the Healthcare sector. Headcount on file is 7.

Over the past 52 weeks the price has ranged from $0.88 to $36.32. The most recent close on file for ISPC is $0.89, dated October 21, 2026. That is −$0.07 (−7.02%) against the previous close. The latest close sits 1.98% above that 52-week low.

Financial Health

In fiscal 2025, iSpecimen Inc. reported revenue of $1.93M. That is −79.24% against the prior fiscal year, when revenue was $9.29M. The same year closed with a net loss of $10.49M. Earnings per share on a trailing basis come to −52.98.

Across the 4 fiscal years on file, revenue moves from $10.40M in 2022 to $1.93M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 4.82 times revenue. On price-to-sales that is 7.77% below the Diagnostics & Research median of 5.23. The medians here are taken across 45 Diagnostics & Research companies that report the metric.

Over the trailing twelve months the total return is −97.29%. Across 5 years the annualized return works out at −82.87%. Beta against the wider market is reported at 1.65. Daily returns over the trailing 5 years annualize to a volatility of 151.91%.

Growth & Income

No dividend is on file for ISPC.

So far in 2026 the total return is −91.42%. Across the complete calendar years on file, 2023 returned −63.56% and 2025 returned −90.21%. Of the 4 complete calendar years on file, 0 finished higher.

Peer Comparison

iSpecimen Inc. (ISPC) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
iSpecimen Inc. ISPC $2.25M —
Thermo Fisher Scientific Inc. TMO $256.61B 37.4
Danaher Corporation DHR $164.40B 41.7
Natera, Inc. NTRA $59.59B —

The Diagnostics & Research industry average P/E ratio is 37.6x. iSpecimen Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$256.61B

 DHR

Danaher Corporation

$164.40B

 NTRA

Natera, Inc.

$59.59B

 A

Agilent Technologies, Inc.

$50.12B

 IQV

IQVIA Holdings Inc.

$45.53B

 WAT

Waters Corporation

$44.92B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About iSpecimen Inc.

iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. The company's marketplace offers human biospecimens, including biofluids, such as whole blood, plasma, serum, urine, saliva, sputum, nasopharyngeal material, and cerebral spinal fluid; solid tissue comprising fresh, fixed, and cryopreserved tissue, as well as formalin-fixed paraffin embedded blocks, slides, and curls; and hematopoietic stem and immune cells, including bone marrow, cord blood, whole blood, or sub-components of these tissues, such as peripheral blood mononuclear cells and other isolated cell types. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Woburn, Massachusetts.

Visit website →